Skip to main content

COVALENT-102

A phase 1/1b clinical trial for patients with KRAS mutant, unresectable, locally advanced and/ metastatic NSCLC, PDAC, and CRC.

About COVALENT-102

This is a multicenter, open-label, non-randomized trial seeking to determine whether BMF-219, either as once daily or twice daily, oral treatment, is safe and effective for patients with patients with KRAS mutations in Non-small cell lung cancer, Pancreatic cancer, and Colorectal cancer.

What is the NCT number for COVALENT-102?

The National Clinical Trial reference number is: NCT05631574

When you talk with your doctor or clinical trial team member, please have the national trial reference number available.

What does it mean it is open label, non-randomized?

It means all patients will receive the BMF-219, the study drug and that the dose level will be pre-allocated. There will be no placebo and the allocation will not be based on chance.

Will it cost me anything?

Study medication and study-related care will be provided at no cost.

Patient eligibility

Age:
18 years & over
Sex:
Female & Male
Conditions:
Solid Tumors

Patients would qualify for the trial if they meet the following criteria:

  • Be 18 years of age or older
  • All sexes included

Have either:

  • NSCLC and at least 2 but no more than 4 previous treatments, or
  • Pancreatic cancer and have received at least one previous treatment, or
  • CRC and have received at least one previous treatment

And also:

  • Have any type of KRAS mutation in their cancer
  • Have not had success with standard of care treatments
  • Had cancer come back or get worse after getting better

The science behind COVALENT-102

Menin, a protein involved in transcriptional regulation, impacting cell cycle control, apoptosis, and DNA damage repair, plays a direct role in oncogenic signaling in multiple cancers. Inhibition of menin is a novel approach to cancer treatment.

In preclinical studies, BMF-219 achieves rapid and near complete reduction of target oncogene expression including NPM1, MYC, HOX, MEIS1, BCL2, and KRAS-related tumors.

 

What is BMF-219?

BMF-219 is an investigational, orally bioavailable small molecule, which covalently binds to the scaffold protein menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. 

Contact us

If you think this clinical trial might be a good fit and you’re interested in taking part, fill out the form below or call our hotline to contact our clinical trials team.

Our clinical trials team will contact you shortly after your form submission.